

Crystallization and preliminary X-ray crystallographic studies of glutamic acid specific proteinase from *Bacillus licheniformis* complex with Z-Leu-Glu-CH₂Cl. By KENGO KITADOKORO, *Shionogi Research Laboratories, Shionogi and Co. Ltd, 5-12-4 Sagisu, Fukushima-ku, Osaka, Japan*

(Received 21 October 1994; accepted 3 January 1995)

Abstract

A glutamic acid specific proteinase from *Bacillus licheniformis* has been crystallized as a complex with the inhibitor Z-Leu-Glu-CH₂Cl. Crystals were grown by the vapor-diffusion method using sodium formate as a precipitant. The crystals diffracted to about 2.0 Å resolution and belonged to the trigonal space group *P*3₁21 (*P*3₂21) with unit-cell parameters $a = b = 134.3$, $c = 109.7$ Å. A total of 26 964 independent reflections were obtained up to 2.2 Å resolution, the merging *R* factor being 0.05 for 42 614 measurements.

Introduction

Glutamic acid specific proteinases from various sources have been reported (Drapeau, Boily & Houmard, 1972; Kakudo, *et al.*, 1992; Yoshida, *et al.*, 1988; Niidome, Yoshida, Ogata, Ito & Noda, 1990; Kitadokoro, *et al.*, 1993). They recognize negatively charged residues of glutamic acid and aspartic acid.

Recently, Nienaber, Breddam & Birkoft (1993) reported the three-dimensional structure of the acidic amino-acid specific proteinase from *Streptomyces griseus*. We also investigated by X-ray analysis the three-dimensional structure of a proteinase with broad substrate specificity (SFase-2), and compared it with the related proteinase structures of *S. griseus* proteinase A and *S. griseus* proteinase B. Based on the SFase-2 structural parameters, the tertiary structure of the acidic amino-acid specific proteinase (SFase-1), which possesses 57% amino-acid sequence identity, was studied to elucidate its substrate-recognition mechanism (Kitadokoro, Tsuzuki, Okamoto & Sato, 1994).

The important key residues for substrate recognition of the acidic amino-acid specific proteinases produced from *Streptomyces* may be the three histidine residues, His158, His168 and His185 (Kitadokoro *et al.*, 1994). The substrate-recognition pocket may be charged positively by this histidine cluster and, therefore, will preferentially recognize the negatively charged Glu and Asp residues on substrate molecules.

Glutamic acid specific proteinase from a pathogenic *Staphylococcus aureus* strain V8 (V8 proteinase) has been widely used as a tool for analysis of the protein sequence (Drapeau *et al.*, 1972). The V8 proteinase has been subjected to nucleotide sequencing (Carmona & Gray, 1987), and also a crystallographic study (Gehrig, Delbaere & Drapeau, 1985). However, its tertiary structure has not been determined. We screened various amino-acid specific proteinases from non-pathogenic microorganisms and found a glutamic acid specific protease from *Bacillus licheniformis* (BLase). Its enzymatic characterization and gene cloning were reported (Kakudo *et al.*, 1992). A glutamic acid specific proteinase from Alcalase™, which has the same protein sequence and character as BLase, was reported by Svendsen & Breddam (1992).

It would be very interesting to study how BLase hydrolyzes the C-terminal bonds of the acidic amino acids Glu and Asp.

As the sequence similarities between SFase-1 and BLase are low (Kitadokoro, *et al.*, 1993), and BLase does not contain the histidine cluster, it may recognize its respective substrates in a different manner from the acidic amino-acid specific proteinases from *Streptomyces*. This paper will discuss the crystallization and preliminary crystallographic data of the BLase complex with its inhibitor of Z-Leu-Glu-CH₂Cl.

Experimental

The glutamic acid specific proteinase (BLase) was purified from culture filtrates of *B. licheniformis*, strain ATCC 14580, as described (Kakudo *et al.*, 1992). Z-Leu-Glu-CH₂Cl was prepared in our laboratory. Purified BLase was inhibited by a tenfold molar excess of Z-Leu-Glu-CH₂Cl in a solution consisting of 10 mM Tris buffer, pH 8.0, 2 mM CaCl₂, and 5% dimethyl sulfoxide, for 1 h at 298 K, concentrated to 10 mg protein ml⁻¹ by use of Centricon 10 tubes (Amicon). The crystallization conditions were screened by the hanging-drop vapor-diffusion method, using the macromolecular crystallization reagent kit, Crystal Screen (Hampton Research). This kit consists of 50 precipitating reagents which were developed by Jancarik & Kim (1991). Each hanging droplet on a siliconized coverslip consisted of 3 µl of the protein solution (10 mg ml⁻¹) plus 3 µl of one of the precipitating reagents. The reservoir contained 0.7 ml of the same reagent.

Crystals were mounted and sealed in 1.0 mm glass capillaries with a small portion of mother liquor. X-ray diffraction






Fig. 1. Crystals of the complex of glutamic acid specific proteinase of *Bacillus licheniformis* with Z-Leu-Glu-CH₂Cl.

photographs were taken at room temperature with a precession camera using Ni-filtered Cu $K\alpha$ radiation from a sealed X-ray tube operated at 40 kV, 35 mA.

X-ray diffraction data were collected using a Rigaku R-Axis IIC imaging plate on a Rigaku R-200 X-ray generator with a fine focus operated at 40 kV and 100 mA. Cu $K\alpha$ X-rays were selected with a graphite monochromator. A single crystal with dimensions $0.5 \times 0.3 \times 0.3$ mm was mounted in a glass capillary.



(a)



(b)

Fig. 2. Precession photographs ($\mu = 10^\circ$) of the (a) $hk0$ and (b) $h0l$ zones of the Z-Leu-Glu-BLase crystals. The crystal-to-film distance was 60 mm, the crystals diffracted to about 2.0 \AA .

Results and discussion

Among 50 precipitants, hexagonal rod-shaped crystals appeared in tube 33 ($4.0 M$ sodium formate, Crystal Screen) at 293 K after 2 weeks. Under the best conditions which were found by surveying around the conditions of tube 33 [$2.8 M$ sodium formate, $0.1 M$ 2-(*N*-morpholino)ethanesulfonic acid buffer, pH 6.5], the crystals grew to a size of $1.0 \times 0.3 \times 0.3 \text{ mm}$ (Fig. 1).

The crystallographic data were obtained by precession photographs taken with an Enraf-Nonius camera. The crystals diffract beyond 2.0 \AA resolution. Fig. 2 shows the precession photographs ($\mu = 10^\circ$) of the $hk0$ zone and the $h0l$ zones, which indicate that the crystals belong to the trigonal space group $P3_121$ ($P3_221$), with cell dimensions $a = b = 134.3$, $c = 109.7 \text{ \AA}$. They are apparently unaffected by several days of exposure to the X-ray beam. Assuming that there are five or six molecules per asymmetric unit, respectively (5 or $6 \times 24 \text{ kDa}$), the volume of the molecule is calculated as 2.74 or $2.28 \text{ \AA}^3 \text{ Da}^{-1}$ and the solvent content is 55.0 or 46.01% , respectively (Matthews, 1968).

A total of 42 614 reflections [$I > \sigma(I)$] up to 2.2 \AA resolution were measured by rotating the crystal from 0 to 30° about the c^* axis with a rotation interval of 1.0° per frame. These data were merged and scaled by the Rigaku software (Sato *et al.*, 1992) to yield 26 964 unique reflections giving an internal merging R factor [$R_{\text{merge}} = \sum |I(h) - \langle I(h) \rangle| / \sum I(h)$, where $I(h)$ and $\langle I(h) \rangle$ are the intensity values of individual measurements and of the corresponding mean values] of 5.5% , comprising 81.9% of all data expected to 2.2 \AA resolution.

The search for suitable heavy-atom derivatives to solve the structure by multiple isomorphous replacement methods is in progress.

The author is grateful to Dr Y. Katsuya, Hyogo Prefectural Institute Industrial Research, for support in data collection and processing. The author also thanks Drs N. Yoshida, H. Teraoka, H. Tsuzuki and T. Sato in our laboratory for their advice. The author would also like to thank Dr K. Watanabe for synthesis of the peptide inhibitor.

References

- CARMONA, C. & GRAY, G. L. (1987). *Nucleic Acids Res.* **15**, 6757.
 DRAPEAU, G. R., BOILY, Y. & HOUMARD, J. (1972). *J. Biol. Chem.* **247**, 6720–6726.
 GEHRIG, L. M. B., DELBAERE, L. T. J. & DRAPEAU, G. R. (1985). *J. Mol. Biol.* **185**, 651.
 JANCARIK, J. & KIM, S.-H. (1991). *J. Appl. Cryst.* **24**, 409–411.
 KAKUDO, S., KIKUCHI, N., KITADOKORO, K., FUJIWARA, T., NAKAMURA, E., OKAMOTO, H., SHIN, M., TAMAKI, M., TERAOKA, H., TSUZUKI, H. & YOSHIDA, N. (1992). *J. Biol. Chem.* **267**, 23782–23788.
 KITADOKORO, K., NAKAMURA, E., TAMAKI, M., HORII, T., OKAMOTO, H., SHIN, M., SATO, T., FUJIWARA, T., TSUZUKI, H., YOSHIDA, N. & TERAOKA, H. (1993). *Biochim. Biophys. Acta*, **1163**, 149–157.
 KITADOKORO, K., TSUZUKI, H., OKAMOTO, H. & SATO, T. (1994). *Eur. J. Biochem.* **224**, 735–742.
 MATTHEWS, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
 NIENABER, V. L., BREDDAM, K. & BIRKTOFT, J. J. (1993). *Biochemistry*, **32**, 11469–11475.
 NIIDOME, T., YOSHIDA, N., OGATA, F., ITO, A. & NODA, K. (1990). *J. Biochem. (Tokyo)*, **108**, 965–970.
 SATO, M., YAMAMOTO, M., IMADA, K., KATSUBE, Y., TANAKA, N. & HIGASHI, T. (1992). *J. Appl. Cryst.* **25**, 348–357.
 SVENDSEN, I. & BREDDAM, K. (1992). *Eur. J. Biochem.* **204**, 165–171.
 YOSHIDA, N., TSURUYAMA, S., NAGATA, K., HIRAYAMA, K., NODA, K. & MAKISUMI, S. (1988). *J. Biochem. (Tokyo)*, **104**, 452–456.